✦ LIBER ✦

Phase II evaluation of topotecan in carcinosarcoma of the uterus: A Gynecologic Oncology Group study

✍ Scribed by David Scott Miller; John A. Blessing; Jeanne Schilder; Adnan Munkarah; Yi Chun Lee

Book ID: 113959971
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 91 KB
Volume: 98
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2005.05.015

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II evaluation of pazopanib in th

A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: A Gynecologic Oncology Group study

✍ Campos, Susana M.; Brady, William E.; Moxley, Katherine M.; O'Cearbhaill, Roisin 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 258 KB

Paclitaxel in the Treatment of Carcinosa

Paclitaxel in the Treatment of Carcinosarcoma of the Uterus: A Gynecologic Oncology Group Study

✍ John P. Curtin; John A. Blessing; John T. Soper; Koen DeGeest 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 36 KB

A phase II evaluation of weekly gemcitab

A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: A gynecologic oncology group study

✍ Brigitte E. Miller; John A. Blessing; Frederick B. Stehman; Mark S. Shahin; S. D 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 239 KB

Phase II Trial of Paclitaxel in Leiomyos

Phase II Trial of Paclitaxel in Leiomyosarcoma of the Uterus: A Gynecologic Oncology Group Study

✍ Gregory Sutton; John A. Blessing; Harrison Ball 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 37 KB

Phase II Trial of Etoposide in Leiomyosa

Phase II Trial of Etoposide in Leiomyosarcoma of the Uterus: A Gynecologic Oncology Group Study

✍ Tate Thigpen; John A. Blessing; Edgardo Yordan; Fidel Valea; Luis Vaccarello 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Phase II evaluation of three-day topotec

Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma : A Gynecologic Oncology Group study

✍ David Scott Miller; John A. Blessing; Samuel S. Lentz; D. Scott McMeekin 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 1 views

## Abstract ## BACKGROUND Topotecan, administeredintravenously at a dose of 1.5 mg/m^2^ per day for 5 days every 21 days, is an established regimen in the treatment of recurrent ovarian carcinoma. Alternate dosing strategies have sought to improve toxicity. The authors evaluated the tolerability a